These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 10982299)

  • 1. Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas.
    Prayson RA; Mohan DS; Song P; Suh JH
    Ann Diagn Pathol; 2000 Aug; 4(4):218-27. PubMed ID: 10982299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myxopapillary ependymomas: a clinicopathologic study of 14 cases including MIB-1 and p53 immunoreactivity.
    Prayson RA
    Mod Pathol; 1997 Apr; 10(4):304-10. PubMed ID: 9110291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 in oligodendroglial neoplasms.
    Castilla EA; Prayson RA; Kanner AA; Rybicki LA; Tubbs RR; Vogelbaum MA; Barnett GH
    Cancer; 2003 Oct; 98(7):1465-72. PubMed ID: 14508834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas.
    McGirt MJ; Chaichana KL; Attenello FJ; Weingart JD; Than K; Burger PC; Olivi A; Brem H; Quinoñes-Hinojosa A
    Neurosurgery; 2008 Oct; 63(4):700-7; author reply 707-8. PubMed ID: 18981880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
    Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
    Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligodendroglioma: does deferring treatment compromise outcome?
    Feigenberg SJ; Amdur RJ; Morris CG; Mendenhall WM; Marcus RB; Friedman WA
    Am J Clin Oncol; 2003 Jun; 26(3):e60-6. PubMed ID: 12796617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
    Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
    Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subependymal giant cell astrocytoma: a clinicopathological study of 23 cases with special emphasis on proliferative markers and expression of p53 and retinoblastoma gene proteins.
    Sharma M; Ralte A; Arora R; Santosh V; Shankar SK; Sarkar C
    Pathology; 2004 Apr; 36(2):139-44. PubMed ID: 15203749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleomorphic xanthoastrocytoma: what do we really know about it?
    Giannini C; Scheithauer BW; Burger PC; Brat DJ; Wollan PC; Lach B; O'Neill BP
    Cancer; 1999 May; 85(9):2033-45. PubMed ID: 10223246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
    Ständer M; Peraud A; Leroch B; Kreth FW
    Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral and salivary gland angiosarcoma: a clinicopathologic study of 29 cases.
    Fanburg-Smith JC; Furlong MA; Childers EL
    Mod Pathol; 2003 Mar; 16(3):263-71. PubMed ID: 12640107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of malignant features in oligodendroglial tumors.
    Saito A; Nakazato Y
    Clin Neuropathol; 1999; 18(2):61-73. PubMed ID: 10192700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 protein alterations in adult astrocytic tumors and oligodendrogliomas.
    Nayak A; Ralte AM; Sharma MC; Singh VP; Mahapatra AK; Mehta VS; Sarkar C
    Neurol India; 2004 Jun; 52(2):228-32. PubMed ID: 15269478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical investigation of p53 and EGFR expression of oligodendrogliomas.
    Broholm H; Bols B; Heegaard S; Braendstrup O
    Clin Neuropathol; 1999; 18(4):176-80. PubMed ID: 10442459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The abnormalities in the p53/p21WAF1 pathway have a significant role in the pathogenesis and progression of gastrointestinal stromal tumors.
    Chou YP; Lin JW; Wang CC; Chiu YC; Huang CC; Chuah SK; Tai MH; Yi LN; Lee CM; Changchien CS; Hu TH
    Oncol Rep; 2008 Jan; 19(1):49-56. PubMed ID: 18097575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of cell cycle regulatory proteins in oligodendroglial tumors.
    Kamiya M; Nakazato Y
    Clin Neuropathol; 2002; 21(2):52-65. PubMed ID: 12005253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Primary retroperitoneal tumors. Treatment modality and prognostic factors].
    Boneschi M; Erba M; Cusmai F; Eusebio D; Miani S; Bortolani EM
    Minerva Chir; 1999 Nov; 54(11):763-8. PubMed ID: 10638149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
    Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
    Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years.
    Luyken C; Blümcke I; Fimmers R; Urbach H; Wiestler OD; Schramm J
    Cancer; 2004 Jul; 101(1):146-55. PubMed ID: 15222000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder.
    Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Comino A; Navone R
    Cancer; 2002 Aug; 95(4):784-90. PubMed ID: 12209722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.